ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Archive

Post Archive: Alex Spira MD PhD FACP

Virginia Cancer Specialists Participating in National Pilot Project to Increase Diversity in Cancer Treatment Trials

October 11, 2021
Read More

Next Oncology Expands Phase I Program with Virginia Cancer Specialists Partnership

October 6, 2021
Read More

A monumental step forward in the treatment of non-small cell lung cancer patients harboring a KRAS mutation, Dr. Christina Brzezniak

June 16, 2021
Read More

Alexander I Spira, MD, PhD, FACP - Sotorasib for Lung Cancers with KRAS p.G12C Mutation, The New England Journal of Medicine

June 4, 2021
Read More

Exploring Why Testing in Lung Cancer is Important to Treatment Decisions - Alex Spira, MD, PhD, FACP

February 23, 2021
Read More

Virginia Cancer Specialists Joins MYLUNG Consortium, Aiming to Advance Use of Precision Medicine for Metastatic Non-Small Cell Lung Cancer Patients

February 4, 2021
Read More

Interview with Dr. Alex Spira - Medpage Today Lung Cancer and Covid19

June 16, 2020
Read More

Alex Spira, MD PhD FACP VCS Co-Author Virginia Cancer Specialists - JAMA Network - Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas Clinical Trial

April 9, 2020
Read More

Alexander Spira, MD, PhD, FACP, on the recent approval of atezolizumab in SCLC

April 2, 2019
Read More

Virginia Cancer Specialists (VCS) Now Offering a Newly FDA-Approved Targeted Therapy for Acute Leukemia

February 4, 2019
Read More